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Combined PET/CT-perfusion in patients
with head and neck cancers might predict
failure after radio-chemotherapy: a proof of
concept study
Carsten Pietsch1,5, Felipe de Galiza Barbosa1, Martin W. Hüllner1,5, Daniel T. Schmid1,5, Stephan K. Haerle2,5,
Gerhard F. Huber2,5, Gabriela Studer3,5, Thomas F. Hany1,5 and Patrick Veit-Haibach1,4,5*
Abstract
Background: [18F]FDG-PET/CT imaging is broadly used in head and neck cancer (HNSCC) patients. CT perfusion
(CTP) is known to provide information about angiogenesis and blood-flow characteristics in tumors. The aim of this
study was to evaluate the potential relationship of FDG-parameters and CTP-parameters in HNSCC preand post-
therapy and the potential prognostic value of a combined PET/CT with CTP.
Methods: Thirteen patients with histologic proven HNSCC were prospectively included. All patients underwent a
combined PET/CT with integrated CTP before and after therapy. Pre- and post-therapeutic data of CTP and PET of
the tumors were compared. Differences were tested using Spearman’s rho test and Pearson’s correlation. A p-value
of p <0.05 was considered statistically significant. Correlations were calculated using Pearson’s correlation. Bootstrap
confidence intervals were calculated to test for additive confidence intervals.
Results: Three patients died due to malignancy recurrence, ten patients were free of recurrence until the end of
the follow-up period. Patients with recurrent disease had significantly higher initial CTP-values compared to the
recurrence-free patients: BFpre 267.4 (171.2)ml/100 mg/min, BVpre 40.9 (8.4)ml/100 mg and MTTpre 8.2 (6.1)sec.
No higher SUVs initially but significantly higher TLG compared to patients without recurrence were found. Post-
therapeutic PET-values differed significantly between the two groups: SUVmaxpost 6.0 (3.2), SUVmeanpost 3.6 (2.0)
and TLG 21751.7 (29794.0).
Conclusion: In our proof of concept study, combined PET/CT with integrated CTP might show complementary
prognostic data pre- and post chemo-radiotherapy. CTP may be used to predict local tumor recurrence, while
FDGPET/CT is still needed for whole-body staging.
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Background
The diagnostic evaluation of head and neck cancer
mainly relies on computed tomography (CT), magnetic
resonance imaging (MRI) and [18F]Fluoro-2-deoxy-D-
glucose-positron emission tomography/computed tom-
ography (FDG-PET/CT). The main goal for work up of
these tumors is local staging and detection of lymph
node metastases as well as distant metastases. However,
CT and MRI provide mainly morphological imaging
while PET/CT provides a combination of metabolic in-
formation e.g. viability of the cell, tumor aggressiveness
and proliferation in head and neck cancer and morpho-
logical information.
CT-Perfusion (CTP) is an imaging tool which provides
functional information too, however, not primarily about
glucose consumption but about perfusion behavior of a
tumor [1–3]. It was shown that CTP has a positive
* Correspondence: patrick.veit-haibach@usz.ch
1Department of Nuclear Nuclear Medicine, University Hospital Zurich,
Ramistrasse 100, 8091 Zuerich, Switzerland
4Department of Diagnostic and Interventional Radiology, University Hospital
Zurich, Zurich, Switzerland
Full list of author information is available at the end of the article
© 2015 Pietsch et al. Open Access This article is distributed under the terms of the Creative Commons Attribution 4.0
International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and
reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to
the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver
(http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.
Pietsch et al. BMC Medical Imaging  (2015) 15:60 
DOI 10.1186/s12880-015-0102-z
correlation with microvessel density and can therefore
partly reflect neo-angiogenesis in tumors. Furthermore,
prognostic impact has been found in several studies
evaluating CTP in head and neck cancer as well as in
other tumor entities [1, 4–7].
Even if CTP and its potential use has been evaluated
for several years, it has not been widely used in clinical
routine so far. On the other hand, FDG-PET/CT is a
broadly used imaging procedure for oncological staging,
therapy follow-up and evaluation of prognosis in a wide
variety of cancer as well as head and neck cancer [7–9].
There is currently insufficient information about the
potential relationship of FDG-parameters [SUVmax,
SUVmean, Tumor Lesion Glycolysis (TLG)] and CTP-
parameters [Blood Flow (BF), Blood Volume (BV) and
Mean Transit Time (MTT)] in head and neck cancer
pre- and post-therapy and the potential impact of
PET/CT-perfusion on how to select patients for the
adequate therapeutic option (e.g. surgery/chemo-
radiotherapy) [10, 11].
The aim of this proof of concept study was 1. to com-
pare and to correlate CTP-parameters (Blood Flow (BF),
Blood Volume (BV) and Mean Transit Time (MTT) and
PET-parameters (SUVmax, SUVmean, Tumor Lesion
Glycolysis (TLG) pre- and post chemo-radiotherapy in
patients with squamous cell carcinoma in the head and
neck (HNSCC) and 2. Evaluate the prognostic value of
such a combined imaging procedure concerning recur-
rence and overall survival in these patients.
Methods
Patients
Overall 41 patients were prospectvely included in a
study with PET/CT and integrated CT-perfusion. Of
those, thirteen patients (mean age: 63 years; range: 44–
78 years; one female, 12 male) received a PET/CT with
CT-perfusion before and after therapy. The excluded pa-
tients hat either 1. only PET/CT without CT-perfusion
or 2. were directly operated after staging or 3. received
(salvage) surgery pre-or post radiochemotherapy during
their cause of disease. Those patients were prospectively
enrolled between 09/2008 and 02/2010. All patients had
clinical suspicion for head and neck cancer and all were
referred for routine primary staging and post-therapy
follow up staging with FDG-PET/CT. The CTP-scan
was integrated into the standard contrast-enhanced
PET/CT-procedure. Patients were included consecu-
tively, no further selection was applied. All patients had
initially a biopsy proven squamous cell carcinoma: Nine
carcinomas of the oropharynx (including three cancers
of base of tongue and three of the tonsils), one oral cav-
ity (floor of the mouth), one larynx carcinoma and two
hypopharynx carcinomas. Eight of these patients had
suspected lymph node metastases at the time of study
enrollment. All patients received radio- and/or chemo-
therapy. Two patients additionally received salvage sur-
gery (after radio- chemotherapy), nine patients received
combined radio/chemotherapy (70Gy), one patient only
chemotherapy and one patient only radiotherapy (70Gy).
Different scientific aspects of the patients included in
this study are already published in a different study [11].
Outcome of patients was assessed regularly based on
local guidelines in our hospital. Patients with advanced
head and neck cancer are seen clinically and with im-
aging after completion of therapy at 3, 6, 12 and
18 month or at occurrence of symptoms. If no recur-
rence is detected, patients are seen clinically every
2 years.
The study was performed in accordance with the regu-
lations of the local institutional review board and ethics
committee (Zurich Cantonal Ethics Committee). Written
informed consent was obtained from all patients before
the examination and enrolment into the study.
Integrated FDG-PET/CT imaging
All data were acquired on a combined PET/CT in-line
system (Discovery VCT, GE Healthcare, Milwaukee, WI,
USA). These dedicated systems integrate a full-ring PET
with a multislice helical 64-slice CT and permit the ac-
quisition of co-registered CT and PET images in the
same procedure. The patients fasted for at least 4 h prior
to the examination. PET/CT imaging with integrated
CTP was started 60 min after the injection of a standard
dose of 300–340 MBq FDG. All patients received a non-
enhanced CT examination which was acquired with the
following parameters: 80 mA, 140 kV, 0.5-s tube rota-
tion, 4.25-mm section thickness. The CT examinations
were acquired during shallow breathing in the head and
neck area, the thorax and the lower abdomen and during
non-forced expiration in the upper abdomen. The CT
examinations included the area from the head to the
upper thighs. The PET emission examination was ac-
quired with an acquisition time of 2 min per bed pos-
ition after the low-dose CT examination. Images (15 cm
axial field-of-view (FOV)/bed position) were recon-
structed by using a standard fully 3D iterative algorithm
(ordered subset expectation maximisation, OSEM:
subsets, 28; iterations, 2; recon matrix, 128 × 128;
overlap, nine slices). The selection of target lesions in
the primary study was based on focal FDG uptake
and the same region was selected in follow-up studies
to CTP scan [11].
After target lesion definition, intravenous contrast in-
jection was started by injecting a total dose of 70 mL
contrast media (Ultravist 370, Bayer Schering Pharma,
Germany). First, 40 mL of contrast media was applied at
a flow of 5 mL/s via a cubital vein, and after a 5-s delay,
the perfusion data were acquired for 50 s in the area of
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interest (1 s rotations time with one image/s, cine dur-
ation 50 s, eight slices, 5 mm slice thickness, 80 mA,
80 kV). Thus, an anatomical craniocaudal coverage of
4 cm was achieved for the perfusion examination of the
target lesion. The first contrast media bolus injection
was followed by a saline flush (20 mL, 5 mL/s). Directly
after the perfusion imaging acquistion, a second bolus of
another 30 mL of contrast media was applied at 4 ml/s
followed by a saline flush of 30 mL to ensure full diag-
nostic (contrast-enhanced) ceCT data of the neck and
thorax because all CTP examinations were fully inte-
grated into the routine, clinical cePET/CT staging and
re-staging examination [11].
Image evaluation
CT-Perfusion evaluation
CTP data were evaluated by a dual-board-certified nu-
clear medicine physician/radiologist with 12 years of hy-
brid imaging experience, using a dedicated workstation
(Advantage Workstation, 4.4, GE Healthcare, Milwau-
kee, WI, USA) with a commercially available perfusion
software with a deconvolution method to calculate the
perfusion values (CT-Perfusion 3, Body-Protocol) [11]. A
freehand ROI defined within the margins of the target
ENT-lesion (primary tumour) was placed in every slice
of the perfusion volume (4 cm coverage, 5 mm slice
thickness) in pre-therapeutic as well as post-therapeutic
studies. In post-therapy scans the ROI was positioned in
the area where tumor was seen in the previous scan.
The calculated time enhancement curve and the para-
metric imaging maps for Blood Flow (BF, ml/100 mg
tissue/min), Blood Volume (BV, ml/100 mg tissue) and
Mean Transit Time (MTT, seconds) were automatically
calculated by the software. The Δ-values (differences)
between pre- and post-therapy scans were calculated
afterwards. The permeability surface product was not
calculated (short study protocol).
Statistical analysis
The pre- and post-therapeutic values for CTP as well as
pre- and post-therapeutic PET parameters were tested
for differences using Spearman’s rho test and Pearson’s
correlation. A p-value of p <0.05 was considered statisti-
cally significant. The correlation between all CT-perfusion
data, the PET-data were and the Δ-values respectively
were calculated using Pearson’s correlation. Secondary
Spearman’s rho test was done for all data mentioned
above. A p-value of p <0.05 was considered statistically
significant. In addition the Bootstrap confidence intervals
for both correlations were calculated to test for additive
confidence intervals. All statistical analyses were per-
formed using SPSS statistical software (Version 16.0.1,
SPSS Inc., Chicago, Ill). To assess the prediction of local
tumor recurrence by means of BVpre and SUVmaxpre,
logistic regression models with stepwise forward entry
were built for BVpre and SUVmax separately and using a
combination of both with bootstrapping (1000 replica-
tions). The goodness-of-fit and the accuracy of the model
were determined using the Hosmer-Lemeshow test
and c-statistics (area under curve of the model).
Results
Patients
In all 13 patients malignant head and neck cancers was
confirmed by histopathology. Staging was determined by
clinical examination and imaging procedures in 11 pa-
tients. In the two patients additionally operated after
chemo-radiotherapy (salvage surgery), clinical stage (see
Table 1) was additionally confirmed by pathology after
surgery. Of the 13 patients, three patients died due to re-
currence of their malignancy during the follow up
period, ten patients were free of recurrence until the end
of the follow up period (of these one patient died of
heart insufficiency 36 months after therapy recurrence
free). The mean follow up period was 48.9 months with
a minimum of 23 months and a maximum of 68 months.
The mean time difference between the end of chemo-
radiotherapy and the second scan was 10 weeks (min 6.7
and max 20 weeks). The mean survival of the patients
with recurrence was 24 months and of the patients free
of recurrence was 56.4 months.
Pre- and post-therapeutic CTP-values and SUV-values of
malignant lesions
First CTP-values and SUV-values, pre- versus postterapeu-
tic including their change (Δ) were compared and all the
mean values demonstrated in the Table 2 (see also Figs. 1
and 2). A comparison between the patients that died with
recurrent disease and the recurrence free patients is shown
in Table 3. Initial CTP-values were higher for the three
patients that died during the follow up period but post-
therapy CTP-values for those patients did not differ
significantly from those without recurrence. Significant
correlation was found between ΔBF and ΔBV (p <0.01).
SUVmaxpre and SUVmeanpre showed no significant
difference between recurrence free patients and the pa-
tients who died, however the pre-therapeutic TLG of re-
currence free patients and the patients who died differed
significantly.
Table 1 Clinical stage at enrolment
Clinical stage (n = 13)
T-stage 2 × T1 7 × T2 2 × T3 2 × T4
N-Stage 4 × N0 1 × N1 2 × N2a
4 × N2b
2 × N2c
M-stage 13 × M0 at enrolment
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There were significant correlations among ΔSUVmax
and ΔTLG (p <0.01) and between ΔSUVmax and ΔSUV-
mean (p <0.05). The post-therapeutic values differed
significantly between the patients that died and the re-
currence free.
Correlation of CT-perfusion data and PET-data
All pre- and posttherapeutic acquired CTP-data (BF,
BV, MTT), the SUV-values (SUVmax, SUVmean,
TLG) and the corresponding Δ-values were corre-
lated (Tables 2 and 3).
No statistically significant correlation was found
among the above mentioned corresponding CTP-
and PET-values nor their Δ-values, respectively. In
addition Bootstrap confidence intervals for these
comparisons also showed no possible correlation
within these intervals.
Regression
Logistic regression models are demonstrated in Table 4,
which summarizes the association between local recur-
rence and the different variables in the various model
steps. Multivariate logistic regression showed that only
SUVmaxpre slightly improved the initial model includ-
ing BVpre alone (c statistics, 0.867 to 0.900). Higher
SUVmaxpre was associated with a decrease in the odds
for developing local recurrence if only BVpre was con-
sidered. This was associated with an increased p-value
for BVpre. BVpre was therefore a significant inde-
pendent predictor (p = 0.003) of local recurrence, with
correct prediction in all three patients. Higher BVpre
was associated with an increase in the odds for devel-
oping local recurrence if only SUVmaxpre was con-
sidered. SUVmaxpre was found to be a borderline
significant independent predictor of local recurrence
(p = 0.040) (Fig. 3).
Discussion
The application and usefulness of CTP and PET/CT in
staging and restaging of head and neck cancer, has been
described before. However, to our knowledge there is no
study evaluating the benefits of combined CTP and
FDG-PET/CT in patients pre- and post radiochemother-
apy in head and neck squamous cell carcinoma
(HNSCC).
Table 2 Pre- and Post-therapeutic mean CTP-values of all malignant lesions and consecutive differences
Pre SDa Post SDa Δ (%)
BF (ml/100 mg/min) 193.4 133.6 69.4 31.8 −64.1
BV (ml/100 mg) 15.9 22.2 5.3 1.6 −66.7
MTT (sec.) 6.1 4.9 7.5 2.9 −23.3
SUVmax 9.4 4.7 3.8 1.6 −59.3
SUVmean 5.8 3.4 2.4 0.9 −58.9
TLG 61.3 × 103 64.7 × 103 27.9 × 103 18.7 × 103 −54.4
Significant correlations were only found between ΔBF and ΔBV (p <0.01). aStandard deviation (SD)
Table 3 Comparison between Pre- and Posttherapeutic CTP-values in patients with recurrence and recurrence free patients
Pre SDb Post SDb Δ (%)
BF (ml/100 mg/min) Disease-free 171.2 123.7 70.2 34.11 −59.0
Recurrence 267.4 161.7 67.1 22.4 −74.9
BV (ml/100 mg) Disease-free 8.4 7.4 4.7 1.7 −34.9
Recurrence 40.9 39.2 5.3 0.7 −88.4
MTT (sec.) Disease-free 6.1 5.0 7.4 2.6 35.9
Recurrence 8.2 3.5 7.8 3.9 −4.5
SUVmax Disease-free 9.3 4.0 3.2a 1.3 −65.5a
Recurrence 10.1 4.7 6.0a 1.6 −40.1a
SUVmean Disease-free 5.7 3.0 2.0a 0.8 −64.7a
Recurrence 6.2 3.0 3.6a 1.2 −41.4a
TLG Disease-free 57.8 × 103a 66.6 × 103 29.8 × 103a 20.3 × 103 −48.4a
Recurrence 79.3 × 103a 51.4 × 103 21.8 × 103a 5.8 × 103 −70.3a
Significant differences are marked with a. Significant differences: TLG differed significantly in the pre-therapeutic scans. The Δ for SUVmax/mean and TLG differed
significantly between patients with recurrence and those recurrence free. The post-therapeutic values for SUVmax/mean and TLG differed significantly between
the patients that died and the recurrence free. Significant correlations: ΔSUVmax and ΔTLG (p <0.01) and ΔSUVmax and ΔSUVmean (p <0.05). bStandard
deviation (SD)
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Current CTP literature
It is already known that elevated blood flow on CTP is
correlated with angiogenesis, microvessel density (MVD)
and increased tumor vascularity, and is has been found
to be correlated with tumor recurrence and the tumor’s
ability to metastasize also in HNSCC [6, 7, 12]. Several
studies also investigated the ability of CTP to predict
therapy success in HNSCC and it was found that pa-
tients with decreased perfusion showed higher local
recurrences [13] and higher perfusion (BV and BF) cor-
related with improved chemotherapy response [14]. Ac-
cordingly, patients with higher pre-treatment BF showed
higher rates of locoregional tumor control [14–16]. One
of the reasons for the ability of prediction of tumor out-
come is assumed to be related to the fact that higher
MVD leads to a higher oxygenation of tumor tissue. As
oxygen is a known radiosensitizer, higher levels of oxy-
genation might lead to higher response rates, especially
to radiation therapy but also concerning the effects of
chemotherapy. This might be one of the reasons why
HNSCC with high perfusion seem to profit from radio-
chemotherapy despite their worse prognosis.
Current PET/CT literature
FDG-PET/CT is well established and widely used in sta-
ging and re-staging of solid tumors, not only in HNSCC
but in a large variety of other tumors as well [10, 11, 17,
18]. It is a well understood pathophysiological concept
that tumor cell metabolism correlates in different ways
with the uptake of FDG (expressed by SUVmax). Hence,
an elevated SUV in tumors might represent the expres-
sion of different intracellular pathways. This need for
glucose in growing tumors can be based on increased
glycolysis, increase of cell proliferation, increased syn-
thesis rate and/or activation of different oncogenic path-
ways. It is also known that this demand for energy is
Table 4 Logistic regression analyses for the prediction of local recurrence
Coefficient SE β estimate 95 % CI p c statistics
(a) Model for the probability of recurrence according to BVpre
BVpre 5.636 1.696 280.418 −0.685 – 6.162 0.08 0.867
(b) Model for the probability of recurrence according to SUVmax
SUVmaxpre 0.036 4.603 1.036 −1.426 – 19.166 0.770 0.600
(c) Model for the probability of recurrence according to BVpre and SUVmax
BVpre 1.992 0.144 7.329 −1.568 – 2.126 0.003
SUVmaxpre −3.048 1.447 0.047 −7.379 – -0.384 0.040 0.900
SE Standard error
CI confidence interval
C-statistics: accuracy of chosen statistical model
β estimate: resulting from a regression analysis hat have been standardized
Fig. 1 71 yo male with squamous cell carcinoma of the larynx. PET/CT. 1a–c axial PET, PET/CT, CT with contrast. Pre-therapeutic scan showing the
tumor (arrow). 2a–c axial PET, PET/CT, CT with contrast. Post-therapeutic scan showing the residual reactive changes without tumor (arrow)
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also related to the production of acids, which are pro-
duced to give the tumor the ability to invade surround-
ing tissues [11]. PET/CT has been used for several years
now for radiotherapy planning as well as for evaluation
and prediction of recurrence [19]. However, there are
partly conflicting results: while several authors con-
cluded that PET/CT is an accurate tool to assess
response after primary treatment of head and neck can-
cer and it is also a potential predictor of outcome after
therapy, studies also recommended close follow-up with
PET/CT to detect local failures [17, 20]. One possible
reason is given by the study of Vainshtein and co-
workers who found very low sensitivies and positive pre-
dictive value (PPV), but high negative predictive value
Fig. 2 71 yo male with squamous cell carcinoma of the larynx. CTP. 1a–c: axial Blood flow, Blood volume, Mean Transit Time. Pre-therapeutic scan
showing the tumor (arrow). 2a-c axial Blood flow, Blood volume, Mean Transit Time. Post-therapeutic scan showing the residual reactive changes
without tumor (arrow)
Fig. 3 ROC (receiver operating characteristics) curves for BVpre and SUVmaxpre vs. local recurrence. BVpre: AUC = 0.867, 95 % CI, 0.616 – 1.000 (p= 0.063);
SUVmaxpre: AUC= 0.600, 95 % CI, 0.210 – 0.990 (p= 0.612); BVpre combined with SUVmaxpre: AUC= 0.900, 95 % CI, 0.724 – 1.000 (p= 0.043). (AUC: area
under curve)
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(NPV) for the prediction of loco-regional failure after ra-
diochemotherapy [18].
CTP and PET/CT
Several studies have shown a good correlation between
BF and SUVmax, respectively SUVmean in primary
staging of HNSCC (as well as other tumors) [8, 12, 16,
21–26]. But there is also literature suggesting an inverse
correlation between SUVmax and BF in HNSCC due to
anaerob glycolysis [27]. Thus, although FDG-uptake can
be considered as an additional marker for tumor charac-
terisation, it might not be able to differentiate which of
the above mentioned pathways is the predominant one.
In those cases, the integrated CTP might be helpful.
In our study we measured initially high CTP values
(BF, BV) during staging of tumor tissue as a possible
marker for high MVD and tumor oxygenation. Interest-
ingly in our study, those patients with recurrent disease
had higher initial CTP-values as a possible marker for a
more aggressive disease as compared to the recurrence-
free patients. However, they did not show higher SUV’s
initially but significantly higher TLG compared to pa-
tient without recurrence. After chemo-radiotherapy the
CTP-values in these patients decreased to levels not
significantly different from those patients without recur-
rent disease. This is partly contradictive to the studies
discussed above where in patients with initially higher
CT-perfusion values a favourable outcome was reported
[28]. However, on the other side our results are in line
with studies discussed in the overview from Preda and
co-workers where CTP-parameters showed significant
correlation with therapy response.
One difference might be that several of the above dis-
cussed manuscript reported about patients with radio-
therapy, while patients in our study mainly received
chemo-radiotherapy. Another reason which has to be ac-
knowledged is the relatively low number of patients – in
our study as well as in discussed manuscripts. We also
found no significant correlation between the metabolic
activity measured by SUVmax, SUVmean and TLG with
the CTP-values. Their Δ-values after chemo-radiotherapy
were not correlated, too.
On the other side, patients who died during follow-up
based on their tumor recurrence had higher SUV-values
after therapy in their follow-up scan and thus, indicating
possible residual tumor. This is at least partly compar-
able to the aforementioned studies about PET/CT in
follow-up of head and neck cancer after therapy where
the metabolic values were found to be accurate and
helpful for detection and prediction of recurrence.
In addition, our study showed that by analysing the
pretherapeutic BV, a prediction of posttherapeutic local
recurrence might be possible. SUVmaxpre was also able
to predict local recurrence, however with borderline
significance. Both parameters showed opposite tenden-
cies, with higher BVpre and lower SUVmaxpre being as-
sociated with the development of local recurrence.
As there was no correlation between CTP- and FDG-
PET/CT-values it seems that PET/CT with integrated
CTP is able to measure two independent factors of
tumor characteristics: on one hand the pre-therapy
CTP-values can be considered a marker for tumor MVD
and the corresponding level of aggressiveness and ex-
pected response to chemo-radiotherapy and overall sur-
vival. On the other hand the post-therapy PET-values
may identify and re-assure the possible failures so that
in those patients might get additional or prolonged ther-
apy and/or more close follow-up. For such a diagnostic/
prognostic and therapy evaluation work-up PET/CT
with integrated CTP might provide complimentary data
in one single examination.
Limitations
We only have a small number of patients and thus, the
results reported here can only serve as a proof of con-
cept and as an indicator of the value of such a combined
imaging approach. Additionally, the post-therapeutic
PET/CT was not always done at the same time point in
all patients. Lastly, the majority, but not all patients re-
ceived the same treatment.
Conclusion
Combined PET/CT with integrated CTP might show
complementary prognostic data pre- and post-chemo-
radiotherapy. CTP may be used to predict local tumor
recurrence, while FDG-PET/CT is still needed for
whole-body staging and might see residual tumours.
Thus, this integrated approach might be used for the
diagnostic and prognostic work-up in head and neck
cancer.
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